News

Tecfidera has a lower risk of discontinuation due to treatment failure than Aubagio in people with multiple sclerosis (MS), a new observational study in Norway suggests. In the study, people receiving Tecfidera (dimethyl fumarate) were 38% less likely to experience treatment failure and stop use than those receiving…

Selma Blair, the TV and film actor who is also a multiple sclerosis (MS) advocate, will headline next month’s second International Virtual Summit for young adults with chronic and rare disorders. Hosted by Health Advocacy Summit (HAS), the Aug. 7-8 event will focus on empowerment, resources, and connection. The event is…

A component of yeast cell walls — called MGCP — prevented disease in a mouse model of multiple sclerosis (MS) by activating anti-inflammatory immune T-cells while suppressing inflammatory T-cells, a study showed. This work also supporting the microbiome’s role in affecting inflammation in autoimmune diseases like MS. “We have…

A potential anti-inflammatory treatment, xB3-IL-1RA was able to reach the central nervous system of a rodent model of multiple sclerosis (MS), and with repeat doses delay disease onset and ease clinical symptoms, according to the investigational therapy’s developer Bioasis Technologies. These findings support the utility of Bioasis’ xB3 peptide…

Three scientists in the U.K. were given awards by the International Progressive MS Alliance that will support projects aiming to explore new approaches to treating progressive forms of multiple sclerosis (MS). The three are among this year’s 19 winners of the alliance’s Research Challenge Awards, which totaled £1.2 million…

Nvidia announced the launch of the U.K.’s most powerful supercomputer — called Cambridge-1 — which uses a combination of artificial intelligence (AI) and simulation to help scientists to better understand complex diseases such as multiple sclerosis (MS) and to design new therapeutics. Cambridge-1 is the first supercomputer designed…

MediciNova announced that it will be given a U.S. patent covering the use of ibudilast (MN-166) in treating eye disease. This oral medication aims to lessen inflammation, including that of progressive multiple sclerosis (MS). Specifically, it will cover ibudilast’s use in  treating injury or damage to the macula —…

Sativex (nabiximols), an oral spray that contains cannabis extracts, was found effective as an add-on therapy for easing spasticity in adult multiple sclerosis (MS) patients who failed to respond to other anti-spastic treatments, a real-world study from Belgium reports. Overall, about 74% patients reported easing of spasticity — muscle stiffness or…

High-potency therapies are more effective at reducing the frequency of symptom relapses in people with secondary progressive multiple sclerosis (SPMS) than low-potency medications, a 10-year study showed. Notably, there was no difference in the effectiveness of either high- or low-potency medicines to limit the progression of disability. “When the…

Using high-efficacy therapies as a first treatment for multiple sclerosis (MS) patients significantly increases the likelihood of having no evidence of disease activity after one and two years, compared to using moderately effective therapies, according to a real-world study of Norwegian patients. However, with each additional attempted treatment, the…

Blacks with multiple sclerosis (MS) have more severe disease and greater disability at their first visit than white patients, even when differences in socioeconomic status are taken into account, a large U.S. study found. The data showed that Black patients with MS had lower scores on some measures of…

Researchers have identified a molecular switch that awakens stem cells in a specific region of the mouse brain — and with their activation, two new types of glia, non-neuronal cells that play critical roles in brain function, also were discovered. Notably, the development of these new glial cell types also…

Alan Thompson, dean of the Faculty of Brain Sciences at University College London (UCL), has won the 2021 Charcot Award, a prize given once every two years for a lifetime of achievement in research into the understanding and treatment of multiple sclerosis (MS). “The Charcot Award is viewed by…

The U.S. Food and Drug Administration has cleared Immunic Therapeutics to initiate two clinical trials of its investigational medication IMU-838 (vidofludimus calcium) in people with relapsing-remitting multiple sclerosis (RRMS), as well as a separate trial for people with progressive types of MS. The RRMS clinical trial program, expected…

Vesicles containing the chemotherapeutic agent doxorubicin can be used to destroy the aberrant, myelin-damaging immune cells that contribute to multiple sclerosis (MS), suppressing the progression of the neurodegenerative disorder, according to recent research findings using a mouse model. If further validated, this technique could provide physicians with a new…

Inherited or familial multiple sclerosis (MS) occurs most frequently in children, women, and people living in warmer climates, a new study suggests. Prevalence rates also differ according to geographical areas, with Canada exhibiting the highest rates and Hungary the lowest. The study, “The global prevalence of familial multiple sclerosis:…

Sleep deprivation may worsen memory in people with clinically isolated syndrome (CIS) or relapsing-remitting multiple sclerosis (RRMS), a new observational study suggests. A link also was observed between a lack of sleep and worse cognitive efficiency in early MS, but that association was caused by the worse moods…

In clinical trials, the investigational anti-CD20 therapy ublituximab was the first to push the annualized relapse rate (ARR) below the 0.1 threshold among patients with relapsing forms of multiple sclerosis (MS), while improving disability outcomes in a significant proportion of patients. “The [relapse] rate was below a tenth…

The Multiple Sclerosis Society of Canada has granted its International Progressive MS Alliance (Alliance) Research Challenge Awards to 19 researchers for their work on progressive forms of multiple sclerosis (MS). Among them is Jennifer Gommerman, PhD, a professor at the University of Toronto, in Canada, who will use…

Abata Therapeutics has opened with $95 million in financing, and plans to use regulatory T-cells to treat autoimmune and inflammatory diseases, starting with progressive forms of multiple sclerosis (MS). Money raised will be used to support work for three clinical trials it plans to initiate in 2025, including…

Long-term disability outcomes tend to be better in people with relapsing-remitting multiple sclerosis (RRMS) who are treated early on with highly effective therapies, a study based on patient registry data indicates. The study, “Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or…

A team of scientists is working on a new delivery method that would use tiny capsules for getting cannabidoil, or CBD, to the brain. According to a study in mice, microcapsules containing cannabidiol can be combined with vesicles carrying a bile acid — an acid found in the gut —…

Treatment with Copaxone (glatiramer acetate), an approved therapy for relapsing forms of multiple sclerosis (MS), while breastfeeding does not appear to be harmful to infants in their first years, a study has found. Investigators observed no differences between infants whose mothers were taking Copaxone and those whose mothers weren’t…

Raised serum neurofilament light chain (sNfL) levels may indicate the presence of brain lesions with chronically active inflammation that are linked with more aggressive forms of multiple sclerosis (MS), a new study suggests. People with high sNfL levels, the study revealed, had greater numbers of chronic inflammation lesions and…

A higher adherence to the MIND diet – short for Mediterranean-Dietary Approach to Stop Hypertension Intervention (DASH) for Neurodegenerative Delay – may protect brain tissue from further damage in people with multiple sclerosis (MS), new research suggests. In particular, consuming more high-fat dairy products was associated with a lower…

Many people with multiple sclerosis (MS) start experiencing symptoms of the disease several years before being diagnosed, a new study suggests. While it has long been known that people with MS tend to seek medical attention more frequently in the years before diagnosis than those without the disease, there…

High levels of kappa-free light chains, or kappa-FLC, in the cerebrospinal fluid (CSF) — the liquid surrounding the brain and spinal cord — may help identify people with clinically isolated syndrome (CIS) who will progress sooner to multiple sclerosis (MS), a study reports. Overall, those with a high…

Long-term use of Kesimpta (ofatumumab) among people with multiple sclerosis (MS) did not substantially lower their antibody levels, allowing them to retain an ability to fight infections, new data from a Phase 3 clinical trial indicate. “These long-term results continue to support Kesimpta as a high-efficacy, first-choice treatment with…

In an effort to make sure those with spinal cord injuries and disorders (SCI/D) are included in disability legislation, the United Spinal Association and some 200 advocates recently gathered virtually for this year’s “Roll on Capitol Hill.” The annual event, in which advocates met with lawmakers, gives organization members…

Multiple sclerosis and its associated fatigue negatively affect school performance, mental health, and physical and social functioning in children and adolescents with the disease, according to a review study. Pediatric-onset multiple sclerosis (POMS) also was associated with negative effects on social functioning, mental health, and quality of life in…